Troglitazone interferes with gemfibrozil's lipid-lowering action.
Bell
D S
DS
Ovalle
F
F
D002839:Chromans / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy; D004347:Drug Interactions; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D012189:Retrospective Studies; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000378:metabolism; D014280:Triglycerides / Q000097:blood*; D000077288:Troglitazone
D002839:Chromans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D014280:Triglycerides; D000077288:Troglitazone; D015248:Gemfibrozil